TrialJournal of clinical pharmacology2016

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval.

Jeanne Mendell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.